{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:46:39Z","timestamp":1793317599226,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Romosozumab following anti-resorptive can be an effective sequential treatment strategy to improve bone strength. However, whether the transition to romosozumab after denosumab is associated with greater improvement in bone mineral density (BMD) and trabecular bone score (TBS) compared with denosumab continuation remains unclear. In this propensity score-matched cohort study, we analyzed data from postmenopausal women who initiated denosumab between 2017 and 2020. Individuals who were transited to 12\u00a0mo of romosozumab after denosumab were 1:1 matched to those who continued an additional 12\u00a0mo of denosumab (n\u00a0=\u200986 for each group; denosumab-romosozumab [DR] and denosumab-denosumab [DD]). Mean BMD gain by denosumab treatment in matched DR and DD groups from denosumab initiation to transition (median 4 times [range 2-8]) was +4.8% and\u2009+2.0% in the lumbar spine (LS) and total hip, respectively. DR group showed greater LS BMD gain compared with the DD group (+6.8 vs +3.3% point, p&amp;lt;.001) for 12\u00a0mo post-transition independent of the duration of prior denosumab treatment, yielding greater overall LS BMD gain in DR compared with DD (+11.6% vs +8.0%, p&amp;lt;.001). DD group showed continued improvement of hip BMD, whereas hip BMD was maintained but not improved in the DR group. DR group was associated with greater TBS improvement than the DD group (2.9% vs 1.0%, p\u2009=\u2009.042). One month after the transition to romosozumab from denosumab, P1NP immediately increased above the level of denosumab initiation with relatively suppressed CTx, creating a transient anabolic window. For 12\u00a0mo follow-up, 1 incident morphometric vertebral fracture and 1 patella fracture were observed in DD, whereas 1 ankle fracture was observed in the DR group. Romosozumab following denosumab improved LS BMD and TBS greater than denosumab continuation in postmenopausal women.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae179","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:17:31Z","timestamp":1730333851000},"page":"184-192","source":"Crossref","is-referenced-by-count":23,"title":["Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8246-1956","authenticated-orcid":false,"given":"Namki","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Internal Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]},{"name":"Yonsei University College of Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]},{"name":"Institute for Innovation in Digital Healthcare (IIDH) , , Seoul 03722 ,","place":["South Korea"]},{"name":"Yonsei University Health System , , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-580X","authenticated-orcid":false,"given":"Sungjae","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism , Department of Internal Medicine, , Goyang 10444 ,","place":["South Korea"]},{"name":"National Health Insurance Service Ilsan Hospital , Department of Internal Medicine, , Goyang 10444 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]},{"name":"Yonsei University College of Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Joon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]},{"name":"Yonsei University College of Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ah","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]},{"name":"Yonsei University College of Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-5638","authenticated-orcid":false,"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]},{"name":"Yonsei University College of Medicine , Endocrine Research Institute, Severance Hospital, , Seoul 03722 ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"8","key":"2025020314460359600_ref1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2025020314460359600_ref2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2025020314460359600_ref3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"5","key":"2025020314460359600_ref4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025020314460359600_ref5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025020314460359600_ref6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025020314460359600_ref7","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2025020314460359600_ref8","doi-asserted-by":"publisher","first-page":"116498","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"issue":"5","key":"2025020314460359600_ref9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"10102","key":"2025020314460359600_ref10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"16","key":"2025020314460359600_ref11","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","journal-title":"N Engl J Med"},{"issue":"15","key":"2025020314460359600_ref12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"2025020314460359600_ref13","doi-asserted-by":"publisher","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12\u2009months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"8","key":"2025020314460359600_ref14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1359\/jbmr.1997.12.8.1316","article-title":"Standardization of femur BMD","volume":"12","author":"Hanson","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025020314460359600_ref15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"1","key":"2025020314460359600_ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"key":"2025020314460359600_ref17","doi-asserted-by":"publisher","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","article-title":"Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"140","author":"Ebina","year":"2020","journal-title":"Bone"},{"key":"2025020314460359600_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101068","article-title":"Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study","volume":"14","author":"Kobayakawa","year":"2021","journal-title":"Bone Rep"},{"issue":"10","key":"2025020314460359600_ref19","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","article-title":"Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study","volume":"32","author":"Tominaga","year":"2021","journal-title":"Osteoporos Int"},{"issue":"9","key":"2025020314460359600_ref20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00198-023-06817-4","article-title":"Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging","volume":"34","author":"Shevroja","year":"2023","journal-title":"Osteoporos Int"},{"issue":"12","key":"2025020314460359600_ref21","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00198-023-06889-2","article-title":"Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis","volume":"34","author":"Hong","year":"2023","journal-title":"Osteoporos Int"},{"issue":"18","key":"2025020314460359600_ref22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167790","article-title":"Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation","volume":"8","author":"Fu","year":"2023","journal-title":"JCI Insight"},{"issue":"12","key":"2025020314460359600_ref23","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae179\/60986579\/zjae179.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/2\/184\/60986579\/zjae179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/2\/184\/60986579\/zjae179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:46:09Z","timestamp":1738575969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/2\/184\/7863360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2025,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae179","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,11,1]]}}}